Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Mini Review
  • Published:

Mini-Review

Monoclonal antibodies and autologous stem cell transplantation for lymphoma

Bone Marrow Transplantation volume 27, pages 565–569 (2001)Cite this article

Abstract

The introduction of monoclonal antibodies into the clinic has paved the way for new approaches to stem cell transplantation for patients with lymphoma. These approaches include the development of new high-dose regimens with radiolabeled antibodies, in vivo purging techniques with the unlabeled antibodies, and post-transplant adjuvant immunotherapy. Numerous trials have demonstrated the feasibility of these approaches. However, questions remain regarding the application of these antibodies including the ultimate efficacy. The recent results of the incorporation of monoclonal antibodies into stem cell transplantation and current research directions are reviewed. Bone Marrow Transplantation (2001) 27, 565–569.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Kohler G, Milstein C . Continuous cultures of fused cells secreting antibody of predefined specificity Nature 1975 256: 495–497

    Article  CAS  Google Scholar 

  2. Nadler LM, Stashenko P, Hardy R et al. Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen Cancer Res 1980 40: 3147–3154

    CAS  PubMed  Google Scholar 

  3. Press OW, Appelbaum F, Ledbetter JA et al. Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas Blood 1987 69: 584–591

    CAS  PubMed  Google Scholar 

  4. Lubeck MD, Steplewski Z, Baglia F et al. The interaction of murine IgG subclass proteins with human monocyte Fc receptors J Immunol 1985 135: 1299–1304

    CAS  PubMed  Google Scholar 

  5. Czuczman MS, Grillo-Lopez AJ, White CA et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy J Clin Oncol 1999 17: 268–276

    Article  CAS  Google Scholar 

  6. Kaminski MS, Zasadny KR, Francis IR et al. Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma J Clin Oncol 1996 14: 1974–1981

    Article  CAS  Google Scholar 

  7. Press OW, Eary JF, Appelbaum FR et al. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support (see comments) New Engl J Med 1993 329: 1219–1224

    Article  CAS  Google Scholar 

  8. Press OW, Eary JF, Appelbaum FR et al. Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas Lancet 1995 346: 336–340

    Article  CAS  Google Scholar 

  9. Liu SY, Eary JF, Petersdorf SH et al. Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue J Clin Oncol 1998 16: 3270–3278

    Article  CAS  Google Scholar 

  10. Press OW, Eary JF, Gooley T et al. A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas Blood 2000 96: 2934–2942

    CAS  PubMed  Google Scholar 

  11. Vose JM, Wahl RL, Saleh M et al. Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas J Clin Oncol 2000 18: 1316–1323

    Article  CAS  Google Scholar 

  12. Witzig TE, White CA, Wiseman GA et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma J Clin Oncol 1999 17: 3793–3803

    Article  CAS  Google Scholar 

  13. Vriesendorp HM, Herpst JM, Germack MA et al. Phase I–II studies of yttrium-labeled antiferritin treatment for end-stage Hodgkin's disease, including Radiation Therapy Oncology Group 87-01 J Clin Oncol 1991 9: 918–928

    Article  CAS  Google Scholar 

  14. Bierman PJ, Vose JM . Data presented at autologous marrow and blood transplantation Proceedings of the Tenth International Symposium, Arlington, Texas 2001

    Google Scholar 

  15. Bierman PJ, Vose JM, Leichner PK et al. Yttrium 90-labeled antiferritin followed by high-dose chemotherapy and autologous bone marrow transplantation for poor-prognosis Hodgkin's disease J Clin Oncol 1993 11: 698–703

    Article  CAS  Google Scholar 

  16. Gribben JG, Freedman AS, Neuberg D et al. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma (see comments) New Engl J Med 1991 325: 1525–1533

    Article  CAS  Google Scholar 

  17. Freedman AS, Neuberg D, Mauch P et al. Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma Blood 1999 94: 3325–3333

    CAS  Google Scholar 

  18. Hale G, Xia MQ, Tighe HP et al. The CAMPATH-1 antigen (CDw52) Tissue Antigens 1990 35: 118–127

    Article  CAS  Google Scholar 

  19. Dyer MJ, Kelsey SM, Mackay HJ et al. In vivo ‘purging’ of residual disease in CLL with Campath-1H Br J Haematol 1997 97: 669–672

    Article  CAS  Google Scholar 

  20. McLaughlin P, Hagemeister FB, Grillo-Lopez AJ . Rituximab in indolent lymphoma: the single-agent pivotal trial Semin Oncol 1999 26: 79–87

    CAS  PubMed  Google Scholar 

  21. Reff M, Leonard J, Newman R et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20 Blood 1994 83: 435–445 (Abstr.)

    CAS  PubMed  Google Scholar 

  22. Golay J, Zaffaroni L, Vaccari T et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis Blood 2000 95: 3900–3908

    CAS  PubMed  Google Scholar 

  23. Harjunpaa A, Junnikkala S, Meri S . Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms Scand J Immunol 2000 51: 634–641

    Article  CAS  Google Scholar 

  24. Demidem A, Lam A, Alas S et al. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs Cancer Chemother Radiopharm 1997 12: 177–186

    CAS  Google Scholar 

  25. Flinn IW, O'Donnell PV, Goodrich A et al. Immunotherapy with rituximab during peripheral blood stem cell transplantation for non-Hodgkin's lymphoma Biol Blood Marrow Transplant 2000 6: 628–632

    Article  CAS  Google Scholar 

  26. Magni M, Di Nicola M, Devizzi L et al. Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion Blood 2000 96: 864–869

    CAS  PubMed  Google Scholar 

  27. Horwitz SM, Breslin S, Negrin RS et al. Rituximab following high dose chemotherapy and autografting in B-cell non-Hodgkin's lymphoma Proc Am Soc Clin Oncol 2000 19: 51a (Abstr.)

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematologic Malignancies, Johns Hopkins Oncology Center, Baltimore, MD, USA

    IW Flinn

  2. Ireland Cancer Center, Case Western Reserve University, Cleveland, OH, USA

    HM Lazarus

Authors
  1. IW Flinn
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. HM Lazarus
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Flinn, I., Lazarus, H. Monoclonal antibodies and autologous stem cell transplantation for lymphoma. Bone Marrow Transplant 27, 565–569 (2001). https://doi.org/10.1038/sj.bmt.1702857

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1702857

Keywords

This article is cited by

Search

Advanced search

Quick links